Holen Sie sich die Stockscreener-App
3.16
0.94%
-0.03
Schlusskurs vom Vortag:
$3.19
Offen:
$3.18
24-Stunden-Volumen:
17,507
Relative Volume:
0.35
Marktkapitalisierung:
$36.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.09M
KGV:
-1.7753
EPS:
-1.78
Netto-Cashflow:
$-17.24M
1W Leistung:
+2.93%
1M Leistung:
+3.61%
6M Leistung:
-0.94%
1J Leistung:
-32.33%
1-Tages-Spanne:
$3.1324
$3.24
1-Wochen-Bereich:
$3.05
$3.24
52-Wochen-Spanne:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.16 | 36.34M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - citybuzz -
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years | LTRN Stock News - GuruFocus
Lung Cancer Patient In Lantern Pharma's Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years - MarketScreener
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years - Yahoo Finance
Two Sigma Investments LP Sells 17,795 Shares of Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma shares sold by major shareholder for $123,600 - Investing.com South Africa
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lantern Pharma sees $208,271 in stock sales by major shareholders - Investing.com
Lantern Pharma (NASDAQ:LTRN) Trading Down 4.4% – Here’s Why - Defense World
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - MSN
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Yahoo Finance
Lantern pharma investors see $168,418 in stock sales By Investing.com - Investing.com Nigeria
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials - BioSpace
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference - marketscreener.com
Lantern Pharma's LP-184 Shows Promise in Pediatric Brain Cancer | LTRN Stock News - GuruFocus
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atyp - GuruFocus
Lantern Pharma’s LP-184 shows promise for pediatric brain cancer - Investing.com
FY2025 EPS Forecast for Lantern Pharma Increased by Analyst - Defense World
Zacks Small Cap Estimates Lantern Pharma Q2 Earnings - Defense World
Lantern Pharma outlines commercialization of radar AI modules and expects LP-184 trial enrollment completion by June 2025 - MSN
LTRN: First Quarter 2025 Financial Results - Yahoo Finance
Lake Street to Host Virtual Meeting Featuring LTRN on May 20 | L - GuruFocus
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance - Investing.com Nigeria
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma’s Earnings Call: Progress and Prospects - TipRanks
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance By Investing.com - Investing.com South Africa
Transcript : Lantern Pharma Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Lantern Pharma Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LTRN) - Seeking Alpha
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss - Investing.com
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss By Investing.com - Investing.com India
Lantern Pharma Q1 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Reports Q1 2025 Financial Results - TipRanks
Lantern Pharma Inc. SEC 10-Q Report - TradingView
Yaber Highlights the Timeless Design and Natural Aesthetic of the T2 Series in "Lunar Rock" Colorway - Barchart.com
Why Beat Earnings When You Can Just Buy The Dip? - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES FIRST QUARTER 2025 RESULTS AND 51% INCREASE IN SALES VOLUMES - Barchart.com
The Ordre des arts et des lettres du Québec announces its 2025 cohortTen luminaries will become honorary members on June 9 - Barchart.com
Abigail Disney Urges Donors To Be Braver About Their Giving And Shouldering More Risk - Barchart.com
STATEMENTWith New Federal Health Minister Installed, It's Time To Get To Work: CMA - Barchart.com
Henry Mauriss Calls For A New Era Of Entrepreneurial Innovation In Media - Barchart.com
Phyllis Waud and Rebecca Murray of Syntax Named to CRN's 2025 Women of the Channel List - Barchart.com
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Tria - GuruFocus
What Is Moving The Markets Now? - Barchart.com
Trump sets 30-day deadline for pharmaceutical companies to lower US drug prices in executive order - Barchart.com
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantern Pharma Inc-Aktie (LTRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.78%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):